Introduction: Candida auris (C. auris) is an emerging nosocomial pathogen, and a sharp rise in cases of colonization and infection has been registered in intensive care units (ICUs) during the ongoing coronavirus disease 2019 (COVID-19) pandemic. The unfavorable resistance profile of C. auris and the potential high mortality of C. auris infections represent an important challenge for physicians.
Methods: We conducted a single-center retrospective study including all patients admitted to ICUs with isolation of C. auris in any non-sterile body site between February 20, 2020, and May 31, 2021. The primary aim of the study was to assess the cumulative incidence of C. auris candidemia in colonized patients. The secondary aim was to identify predictors of C. auris candidemia in the study population.
Results: During the study period, 157 patients admitted to ICUs in our hospital became colonized with C. auris; 59% of them were affected by COVID-19. Overall, 27 patients (17%) developed C. auris candidemia. The cumulative risk of developing C. auris candidemia was > 25% at 60 days after first detection of C. auris colonization. Seven patients with C. auris candidemia (26%) also developed a late recurrent episode. All C. auris blood isolates during the first occurring episode were resistant to fluconazole and susceptible to echinocandins, while 15 (56%) were resistant to amphotericin B. During late recurrent episodes, emergent resistance to caspofungin and amphotericin B occurred in one case each. In the final multivariable model, only multisite colonization retained an independent association with the development of C. auris candidemia.
Conclusion: Candida auris candidemia may occur in up to one fourth of colonized critically ill patients, and multisite colonization is an independent risk factor for the development of candidemia. Implementing adequate infection control measures remains crucial to prevent colonization with C. auris and indirectly the subsequent development of infection.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995918 | PMC |
| http://dx.doi.org/10.1007/s40121-022-00625-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Candidemia chronicles: Retrospective analysis of candidemia epidemiology, species distribution, and antifungal susceptibility patterns in Bahrain.
World J Virol
December 2024
Department of Pediatric, Faculty of Medicine, Tanta University, Tanta 31511, Egypt.
Background: Invasive fungal infections, particularly candidemia, pose significant clinical challenges globally. Understanding local epidemiology, species distribution, and antifungal susceptibility patterns is crucial for effective management despite regional variations.
Aim: To investigate the epidemiology, species distribution, antifungal susceptibility patterns, and associated risk factors of candidemia among patients in Bahrain from 2021 to 2023.
Mortality patterns in candidemia: Insights from a multispecies analysis using a global research network.
Med Mycol
December 2024
Department of Medicine, Division of Infectious Diseases, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Understanding the impact of different Candida species on patient outcomes is crucial for effective management and treatment strategies. This study aims to comprehensively analyze the association between Candida species and mortality in documented candidemia. We queried TriNetX, a global research network database, to identify patients diagnosed with candidemia through polymerase chain reaction from 2020 to 2023.
View Article and Find Full Text PDF: Epidemiology Update and a Review of Strategies to Prevent Spread.
J Clin Med
November 2024
Division of Infectious Diseases, Department of Medicine, College of Medicine, University of Arizona, Tucson, AZ 85724, USA.
Article Synopsis
- Candida auris is a rapidly spreading fungal pathogen that poses serious health risks and has led to considerable illness and death.
- The review highlights current understanding of its epidemiology and effective strategies to prevent its spread and outbreaks.
- Future research directions are also explored to better manage and combat this emerging threat.
Rezafungin acetate for the treatment of candidemia and invasive candidiasis: a pharmacokinetic evaluation.
Expert Opin Drug Metab Toxicol
November 2024
Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Australia.
Introduction: Rezafungin, formerly SP3025 and CD101, is a next-generation echinocandin, chemically related to anidulafungin, with differentiated pharmacokinetic characteristics, including a prolonged half-life allowing extended-interval dosing.
Areas Covered: Herein, we discuss the role of rezafungin in the treatment of candidemia and invasive candidiasis, with a specific focus on pharmacokinetics considerations.
Expert Opinion: Rezafungin exhibits potent in vitro activity against most wild-type and azole-resistant species, including .
fungaemia outbreak in a tertiary care academic hospital and emergence of a pan-echinocandin resistant isolate, Greece, 2021 to 2023.
Euro Surveill
November 2024
Clinical Microbiology Laboratory, "Attikon" University General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Article Synopsis
- - After COVID-19 began, there was a significant increase in invasive fungal infections globally, but the specific situation in Greece regarding fungaemias remains unclear.
- - An ongoing outbreak in a Greek hospital has led to 89 episodes of bloodstream infections over nearly three years, with these episodes occurring in waves linked to previous colonization peaks.
- - Most fungal isolates were found to be resistant to fluconazole but sensitive to other antifungals, highlighting the importance of infection control and careful use of antifungal treatments to prevent resistance.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!